Addressing the GAPs in Alzheimer’s Trials, Treatment

The Global Alzheimer’s Platform (GAP) Foundation, an organization dedicated to improving Alzheimer’s clinical trials in the quest of a cure, has just wrapped the GAP-NET Site Optimization Conference in Nashville. The Feb. 27-March 1 meeting brought together approximately 150 representatives from its network of Alzheimer’s clinical research sites. The third annual GAP-NET conference attracted the […]

Read More…

Boosting Alzheimer’s trial participation via Medicare Advantage “memory fitness programs”

Clinical trials represent future hope for patients seeking better care, and there is no disease more in need of better care than Alzheimer’s disease. While death rates among most cancers, as well as heart disease, HIV-related illness, and other categories, have declined in the past decade, there has been no progress for Alzheimer’s disease. Better […]

Read More…

A Cure for Alzheimer’s is Not Possible Without You

There are many open, important clinical trials in Tennessee right now targeting Alzheimer’s disease and related conditions. It’s been 18 months since Nashville legend Glen Campbell died after a long battle with Alzheimer’s disease. Glen and his family bravely shared his heartbreaking journey in the hope of inspiring better care and research for the disease, […]

Read More…

Top Alzheimer’s Researchers Hope That Near-100 Dementia Drugs in Trials Are Moving Closer to a Breakthrough

Top Alzheimer’s Researchers Hope That Near-100 Dementia Drugs in Trials Are Moving Closer to a Breakthrough The search for a drug to treat Alzheimer’s disease, the most common form of dementia, has been marked by clinical trial failures. A new report from top researchers says the number of drugs advancing through clinical phase two and […]

Read More…

How a Raleigh Clinic is Helping Alzheimer’s Patients

Alzheimer’s clinical trial participants are getting a lift to their appointments at Raleigh Neurology Associates. The Global Alzheimer’s Platform Foundation, in partnership with Lyft, is providing transportation to participants in an Eli Lilly study testing a therapy to attack plaque in the brain characteristic of Alzheimer’s disease. Sean Walsh, director of clinical research at Raleigh Neurology Associates, says the new […]

Read More…

Can GAP double the number of patients in Alzheimer’s trials?

Curing diseases requires new drugs. Getting those new drugs approved by regulators requires data from successful clinical trials. Those trials depend on patients, and right now getting those patients is a challenge for many sponsor companies. According to research performed on recruitment, 85 percent of trials are delayed due to enrollment issues and more than […]

Read More…

Patient Advocacy Groups Welcome 40% Increase in Alzheimer’s NIH Research Funds Authorized by Congress

The U.S. Congress last week authorized an additional 40 percent in funds for Alzheimer’s disease (AD) research, boosting the fiscal 2017 total by $400 million to nearly $1.4 billion as part of a $2 billion year-over-year increase for the National Institutes of Health (NIH). The final package won praise from the nonprofit Global Alzheimer’s Platform Foundation (GAP), […]

Read More…

Hope to Prevent Alzheimer’s? Grab the Olive Oil and Hop on a Treadmill

Ann Poehler’s strides quicken on the treadmill. Her feet pound. Her heart races from 150 to 160 beats per minute and more. A plastic tube jutting from the Prairie Village woman’s mouth feeds carbon dioxide levels to a computer here inside the University of Kansas Alzheimer’s Disease Center. The computer records every respiration while an exercise […]

Read More…

National Survey Finds that a Majority of Americans Would Consider Participating in an Alzheimer’s Clinical Trial

A recent online survey conducted by Harris Poll found that nearly 60% of Americans are definitely willing or willing to consider taking part in a clinical trial for Alzheimer’s. This promising statistic is good news for researchers; however, obtaining qualified trial participants has been one of the greatest challenges in getting clinical trials off the […]

Read More…